ImpediMed

ImpediMed R&D Expenses

The Research & Development Expenses of ImpediMed (IPD.AX) as of Nov 12, 2026 is 150,000.00 AUD. In the previous year, Research & Development Expenses was 221,000.00 AUD — a change of -32.13% (lower).

R&D Expenses

150,000.00AUD

YoY

-32.13%

Last updated:

Research & Development Expenses of ImpediMed is 2025 150,000.00 AUD. Research & Development Expenses of ImpediMed was 2024 221,000.00 AUD. It decreases by -32.13% lower compared to the previous year.

The ImpediMed R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
2.96 M AUD
Jan 1, 2019
3.37 M AUD
Jan 1, 2020
3.31 M AUD
Jan 1, 2021
1.46 M AUD
Jan 1, 2022
683,000.00 AUD
Jan 1, 2023
598,000.00 AUD
Jan 1, 2024
221,000.00 AUD
Jan 1, 2025
150,000.00 AUD
The ImpediMed R&D Expenses history
YEARR&D ExpensesYoY
150,000.00AUD-32.13%
221,000.00AUD-63.04%
598,000.00AUD-12.45%
683,000.00AUD-53.09%
1.46 MAUD-55.99%
3.31 MAUD-1.69%
3.37 MAUD+13.53%
2.96 MAUD-44.45%
5.34 MAUD+32.05%
4.04 MAUD+290.43%
1.04 MAUD+158.10%
401,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Research & Development Expenses of ImpediMed is 150,000.00 AUD in 2025.

Research & Development Expenses of ImpediMed changed from 221,000.00 AUD to 150,000.00 AUD, representing a -32.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses ImpediMed since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ImpediMed

All Key Metrics — ImpediMed